Table 1 Clinical trials of OVs combination therapy with immune checkpoint inhibitors
From: Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages
| Â | Virus | RoA | Combination | Cancer | Trial No | Phase | Status |
|---|---|---|---|---|---|---|---|
Adenovirus | TILT-123 | IT | Avelumab | Advanced solid tumors | NCT05222932 | I | Recruiting |
| Â | H101 | Intravesical | Camrelizumab | Bladder cancer | NCT05564897 | II | Recruiting |
| Â | NG-350A | IV | Pembrolizumab | Epithelial tumors | NCT05165433 | I | Recruiting |
| Â | TILT-123 | IT/IP | Pembrolizumab | Ovarian cancer | NCT05271318 | I | Recruiting |
Herpes simplex virus | T-VEC | IT | Panitumumab | Squamous cell carcinoma | NCT04163952 | I | Active, not recruiting |
| Â | HX-008 | IT | Anti-PD-1 monoclonal antibody | Melanoma | NCT05068453 NCT05070221 | I | Not yet recruiting |
| Â | RP2/RP3 | IT | Atezolizumab/Atezolizumab | Colorectal carcinoma | NCT05733611 | II | Not yet recruiting |
| Â | VG161 | IT | Nivolumab | Pancreatic cancer | NCT05162118 | I/II | Recruiting |
Vaccinia virus | MQ710 | IT | Pembrolizumab | Solid Tumors | NCT05859074 | I | Recruiting |
| Â | ASP9801 | IT | Pembrolizumab | Advanced/Metastatic solid tumors | NCT03954067 | I | Active, not recruiting |
| Â | TBio-6517 | IT/IV | Pembrolizumab | Advanced solid tumors | NCT04301011 | I/IIa | Active, not recruiting |
| Â | BT-001 | IT | Pembrolizumab | Advanced solid tumors | NCT04725331 | I/IIa | Recruiting |
Reovirus | PeLareorEp | IV | Avelumab | Breast cancer | NCT04215146 | II | Active, not recruiting |
Vesicular stomatitis virus | Revottack | IV | Toripalimab | Advanced malignant solid tumor | NCT05644509 | I | Not yet recruiting |
Chimeric orthopoxvirus | CF33-hNIS | IT/IV | Pembrolizumab | Advanced solid tumor | NCT05346484 | I | Recruiting |
M1 virus | M1-c6v1 | IV | Camrelizumab | Hepatocellular carcinoma | NCT04665362 | I | Not yet recruiting |